AK104 plus chemotherapy for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests AK104 (an antibody medicine) given with standard chemotherapy as the first treatment for advanced pancreatic ductal cancer. It aims to see whether this combination works better and is safe for people with cancer that has spread or is advanced.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 75 and able to sign consent before any study tests or treatments
- Have pancreatic ductal adenocarcinoma confirmed by biopsy or other tumor sample (not other pancreatic tumor types)
- Not have had chemo or other whole-body cancer treatment for advanced or metastatic pancreatic cancer before (with limited exceptions)
- Have at least one measurable tumor spot on scans (and it should not be only a previously radiated spot unless it clearly worsened)
- Be well enough to do usual activities (ECOG 0 or 1) and expected to live at least 3 months
- Not be pregnant or breastfeeding, and use effective birth control during treatment and for 120 days after last dose (also applies to men with partners who can become pregnant)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (FG-M108) combined with chemotherapy for pancreatic cancer that is advanced or has spread. The medicine targets a protein found on some pancreatic cancer cells, and the goal is to see if it helps shrink tumors or slow the cancer more than chemotherapy alone.
This trial tests a combination of two investigational drugs, AK130 and AK112, for people with advanced pancreatic cancer. It may be an option if you have had 1 or 2 prior treatments and are still relatively healthy.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This Phase 1/2 trial tests a new medicine (IN10018) and a specific added antibody (KN046) together with standard chemotherapy for advanced pancreatic cancer. It aims to see whether this combination can better control the cancer and how safely it can be given.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.